Valuation : Zai Lab Limited

Market Cap 294.47Cr 4.98TCr 253.25Cr 238.19Cr 217.43Cr 406.65Cr 28TCr 407.96Cr 2.82TCr 1.09TCr 14TCr 1.11TCr 1.08TCr 45TCr P/E 2026 *
-11.9x
P/E 2027 * -11.8x
Enterprise Value 248.71Cr 4.21TCr 213.89Cr 201.17Cr 183.64Cr 343.45Cr 24TCr 344.56Cr 2.39TCr 921.99Cr 12TCr 934Cr 913.58Cr 38TCr EV / Sales 2026 *
5.7x
EV / Sales 2027 * 4.64x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
3 years 270.64
Extreme 270.64
810
5 years 270.64
Extreme 270.64
2,446.85
10 years 270.64
Extreme 270.64
3,693.35
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+43.36%-.--% - - 294.47Cr
-1.87%+3.58%+44.36%+0.30% 8.27TCr
-0.64%-0.19%-19.40%-36.50% 6.02TCr
-2.23%+3.71%+478.96%+34.33% 5.81TCr
+1.31%-3.43%-7.43%+31.70% 4.97TCr
-0.14%-2.32%+1.64%+153.86% 4.67TCr
-1.64%+1.93%+56.98%-15.50% 3.26TCr
-0.98%+2.86%+46.30%+99.76% 2.57TCr
-2.52%-2.81%-1.74%+157.83% 2.27TCr
-1.06%+0.04%+62.93%+104.73% 1.65TCr
Average +3.35%+0.10%+73.62%+58.95% 4.39TCr
Weighted average by Cap. -0.74%+1.00%+86.31%+40.39%

Financials

2026 *2027 *
Net sales 44Cr 738.38Cr 38Cr 35Cr 32Cr 60Cr 4.13TCr 60Cr 418.6Cr 161.8Cr 2.11TCr 163.91Cr 160.33Cr 6.73TCr 55Cr 934.05Cr 47Cr 45Cr 41Cr 76Cr 5.22TCr 76Cr 529.52Cr 204.68Cr 2.67TCr 207.35Cr 202.81Cr 8.52TCr
Net income -24Cr -407.13Cr -21Cr -19Cr -18Cr -33Cr -2.28TCr -33Cr -230.81Cr -89Cr -1.17TCr -90Cr -88Cr -3.71TCr -21Cr -357.08Cr -18Cr -17Cr -16Cr -29Cr -2TCr -29Cr -202.44Cr -78Cr -1.02TCr -79Cr -78Cr -3.26TCr
Net Debt -46Cr -774.22Cr -39Cr -37Cr -34Cr -63Cr -4.33TCr -63Cr -438.91Cr -169.66Cr -2.22TCr -171.87Cr -168.11Cr -7.06TCr -38Cr -644.23Cr -33Cr -31Cr -28Cr -53Cr -3.6TCr -53Cr -365.22Cr -141.17Cr -1.84TCr -143.01Cr -139.89Cr -5.87TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
26.23USD
Average target price
33.14USD
Spread / Average Target
+26.34%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!